Jeff Jones
Stock Analyst at Oppenheimer
(3.76)
# 958
Out of 5,182 analysts
94
Total ratings
34.88%
Success rate
14.97%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Initiates: Outperform | $10 | $4.41 | +126.76% | 1 | Apr 16, 2026 | |
| ALMS Alumis | Maintains: Outperform | $50 → $55 | $24.75 | +122.22% | 4 | Mar 30, 2026 | |
| PTHS Pelthos Therapeutics | Maintains: Outperform | $60 → $62 | $24.77 | +150.30% | 4 | Mar 20, 2026 | |
| PHAR Pharming Group | Reiterates: Outperform | $42 → $41 | $16.68 | +145.80% | 1 | Mar 13, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $32 → $33 | $15.92 | +107.29% | 7 | Mar 13, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $53 → $57 | $10.08 | +465.48% | 11 | Mar 10, 2026 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $44 → $50 | $30.33 | +64.85% | 4 | Mar 6, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $86.68 | +38.44% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.54 | +1,523.38% | 9 | Aug 27, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $5.41 | +214.23% | 4 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $86 | $28.56 | +201.12% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $3.47 | +418.73% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.61 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $4.27 | +274.71% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.21 | +3,619.01% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.32 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $4.80 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.30 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.44 | +941.67% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $2.54 | +73,718.90% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $4.18 | +26,215.79% | 2 | Nov 17, 2022 |
Aclaris Therapeutics
Apr 16, 2026
Initiates: Outperform
Price Target: $10
Current: $4.41
Upside: +126.76%
Alumis
Mar 30, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $24.75
Upside: +122.22%
Pelthos Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $60 → $62
Current: $24.77
Upside: +150.30%
Pharming Group
Mar 13, 2026
Reiterates: Outperform
Price Target: $42 → $41
Current: $16.68
Upside: +145.80%
Corvus Pharmaceuticals
Mar 13, 2026
Reiterates: Outperform
Price Target: $32 → $33
Current: $15.92
Upside: +107.29%
Corbus Pharmaceuticals Holdings
Mar 10, 2026
Maintains: Outperform
Price Target: $53 → $57
Current: $10.08
Upside: +465.48%
ArriVent BioPharma
Mar 6, 2026
Reiterates: Outperform
Price Target: $44 → $50
Current: $30.33
Upside: +64.85%
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $86.68
Upside: +38.44%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.54
Upside: +1,523.38%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $5.41
Upside: +214.23%
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $28.56
Upside: +201.12%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $3.47
Upside: +418.73%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.61
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $4.27
Upside: +274.71%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.21
Upside: +3,619.01%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $7.32
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $4.80
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.30
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.44
Upside: +941.67%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $2.54
Upside: +73,718.90%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $4.18
Upside: +26,215.79%